Zevenbergen Capital Investments LLC Boosts Stock Holdings in DexCom, Inc. $DXCM

Zevenbergen Capital Investments LLC increased its position in DexCom, Inc. (NASDAQ:DXCM) by 10.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 685,433 shares of the medical device company’s stock after acquiring an additional 62,098 shares during the period. Zevenbergen Capital Investments LLC’s holdings in DexCom were worth $46,123,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Andra AP fonden bought a new stake in shares of DexCom in the 2nd quarter worth $26,000. Twin Peaks Wealth Advisors LLC purchased a new stake in shares of DexCom during the second quarter valued at $26,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in DexCom in the 2nd quarter worth about $45,000. Anderson Financial Strategies LLC purchased a new position in DexCom in the 1st quarter worth about $37,000. Finally, Nkcfo LLC bought a new position in DexCom during the 2nd quarter valued at about $69,000. 97.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Morgan Stanley upgraded shares of DexCom from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $63.00 to $75.00 in a research note on Tuesday, December 2nd. Stifel Nicolaus started coverage on DexCom in a report on Tuesday, October 21st. They set a “buy” rating and a $85.00 price target on the stock. Cowen restated a “buy” rating on shares of DexCom in a research note on Friday, October 24th. Sanford C. Bernstein reiterated an “outperform” rating and set a $84.00 price objective on shares of DexCom in a research report on Monday, November 3rd. Finally, JPMorgan Chase & Co. dropped their target price on DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.61.

DexCom Price Performance

Shares of DexCom stock opened at $66.05 on Friday. The stock has a market cap of $25.76 billion, a P/E ratio of 36.69, a P/E/G ratio of 1.42 and a beta of 1.51. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56. The stock’s fifty day moving average is $63.94 and its 200 day moving average is $73.84. DexCom, Inc. has a one year low of $54.11 and a one year high of $93.25.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The business had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter in the prior year, the business posted $0.45 earnings per share. The business’s quarterly revenue was up 21.6% on a year-over-year basis. Sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Several broker notes and target raises lift sentiment: Canaccord Genuity initiated/maintained a Buy and Mizuho reiterated optimism (including a price-target raise to $78), while Robert W. Baird kept a Buy rating — these research calls support upside expectations for DXCM. Dexcom Gets a Buy from Canaccord Mizuho raises PT to $78 Baird keeps Buy
• Neutral Sentiment: Analyst coverage pieces (e.g., Mizuho / other note coverage) and retrospective pieces highlighting that DXCM has lost ~43% over three years give context to valuation and risk but don’t change near-term fundamentals by themselves. Investors lost 43% over 3 years Mizuho Forecasts Strong Price Appreciation
• Negative Sentiment: Multiple law firms have issued class-action notices and solicitations (Levi & Korsinsky, Schall Law, Gross Law, Halper Sadeh, Schall, Schall Law Firm), indicating potential securities litigation tied to alleged disclosures between 2024–2025; this creates legal overhang and downside risk for shareholders. Levi & Korsinsky class action notice Halper Sadeh notice Schall Law Firm notice Gross Law Firm reminder
• Negative Sentiment: Investor letters and analysis cite modest guidance as a driver of recent share weakness; lingering concerns on near-term growth/operating cadence could limit upside despite analyst optimism. Modest guidance cited as reason for fall

Insiders Place Their Bets

In other DexCom news, Director Richard Alexander Collins sold 2,906 shares of DexCom stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $59.05, for a total transaction of $171,599.30. Following the transaction, the director owned 35,088 shares of the company’s stock, valued at $2,071,946.40. The trade was a 7.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jacob Steven Leach purchased 18,200 shares of the company’s stock in a transaction on Monday, November 10th. The stock was purchased at an average price of $55.04 per share, with a total value of $1,001,728.00. Following the completion of the transaction, the chief operating officer owned 331,697 shares of the company’s stock, valued at approximately $18,256,602.88. This trade represents a 5.81% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have sold 7,866 shares of company stock worth $448,177. Company insiders own 0.32% of the company’s stock.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.